{"entity":{"id":"nct07208539","kind":"trial","name":"AG Followed by FOLFIRINOX Both Combined With PD-L1 Antibodies as a Conversion Therapy for Borderline Resectable and Locally Advanced Pancreatic Cancer.","aka":["ZSPAC-14"],"tldr":"A phase 2 trial in pancreatic cancer, run by Shanghai Zhongshan Hospital, not yet recruiting.","summary":"AG Followed by FOLFIRINOX Both Combined With PD-L1 Antibodies as a Conversion Therapy for Borderline Resectable and Locally Advanced Pancreatic Cancer. is a phase 2, interventional study registered as NCT07208539 by Shanghai Zhongshan Hospital, with a registry enrolment figure of 77 participants, started 2025-10-10 and due to reach its primary completion in 2026-04-09. Interventions recorded: Treatment: AG & anti-PD-L1 + FOLFIRINOX & anti-PD-L1. Conditions listed: Pancreatic Cancer. Primary outcome: 18-month overall survival (OS) rate. Pancreatic eligibility wording from the registry: \"* According to the NCCN Clinical Practice Guidelines for Pancreatic Cancer (2024\". No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07208539","url":"https://clinicaltrials.gov/study/NCT07208539"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["borderline-resectable-pdac","resectable-pdac","locally-advanced-pdac"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07208539","phase":"2","setting":"A Prospective, Double-cohort, Multicenter, Phase II Study of Gemcitabine and Albumin Paclitaxel in Combination With PD-L1 Antibodies Followed by Liposomal Irinotecan Combined With Oxaliplatin, 5-FU/LV and PD-L1 Antibodies as Conversion Therapy for Borderline Resectable/Local Advanced Pancreatic Cancer","sponsor":"Shanghai Zhongshan Hospital","enrolled":77,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07208539/","neighbours":{"cancer":[{"id":"borderline-resectable-pdac","kind":"cancer","name":"Borderline resectable pancreatic ductal adenocarcinoma","route":"/cancers/borderline-resectable-pdac/"},{"id":"locally-advanced-pdac","kind":"cancer","name":"Locally advanced unresectable pancreatic ductal adenocarcinoma","route":"/cancers/locally-advanced-pdac/"},{"id":"resectable-pdac","kind":"cancer","name":"Resectable pancreatic ductal adenocarcinoma","route":"/cancers/resectable-pdac/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}